Which is the most common adverse effect of aminoglycosides that limits their clinical use?

Explanation

## Most Common Adverse Effect of Aminoglycosides ### Nephrotoxicity as the Dose-Limiting Toxicity **Key Point:** Nephrotoxicity is the most common and clinically significant adverse effect of aminoglycosides, occurring in 5–25% of patients receiving prolonged therapy. It is the primary reason for dose adjustment and monitoring in clinical practice. ### Mechanism of Aminoglycoside Nephrotoxicity Aminoglycosides accumulate in the proximal tubular cells via endocytosis and cause: 1. Direct tubular epithelial cell damage 2. Acute tubular necrosis (ATN) in severe cases 3. Non-oliguric acute kidney injury (most common presentation) 4. Reversible elevation of serum creatinine ### Risk Factors for Nephrotoxicity | Risk Factor | Mechanism | |---|---| | **Prolonged therapy (>7–10 days)** | Cumulative renal accumulation | | **High trough levels** | Saturation of proximal tubular uptake | | **Pre-existing renal disease** | Reduced clearance | | **Dehydration/volume depletion** | Decreased renal perfusion | | **Concurrent nephrotoxic drugs** | Additive tubular injury (NSAIDs, ACE-I, amphotericin B) | | **Advanced age** | Reduced GFR | | **Sepsis** | Systemic inflammation + renal hypoperfusion | ### Clinical Features - **Onset:** Usually after 5–7 days of therapy - **Pattern:** Non-oliguric AKI (urine output often preserved) - **Reversibility:** Generally reversible upon discontinuation - **Monitoring:** Serial serum creatinine, urinalysis for casts **High-Yield:** Once-daily dosing (e.g., gentamicin 7 mg/kg once daily) reduces nephrotoxicity compared to thrice-daily dosing because it minimizes peak concentrations in renal tissue while maintaining bactericidal effect. ### Comparison with Other Aminoglycoside Toxicities | Toxicity | Frequency | Reversibility | Onset | Monitoring | |---|---|---|---|---| | **Nephrotoxicity** | 5–25% | Reversible | 5–7 days | Creatinine, BUN | | **Ototoxicity** | 2–8% | Often irreversible | Variable | Audiometry | | **Neuromuscular blockade** | Rare (<1%) | Reversible | Acute | Muscle strength | | **Hepatotoxicity** | Very rare | Reversible | Variable | LFTs | **Clinical Pearl:** Ototoxicity, while serious and potentially irreversible, is less common than nephrotoxicity. Neuromuscular blockade is a rare complication seen mainly in myasthenia gravis or with concurrent use of neuromuscular blocking agents. **Warning:** Do not confuse frequency with severity — ototoxicity may be less common but is irreversible, whereas nephrotoxicity is usually reversible. However, the question asks for the "most common" effect, which is nephrotoxicity. ### Prevention Strategies 1. **Dose adjustment** based on renal function (using nomograms or TDM) 2. **Once-daily dosing** regimens 3. **Adequate hydration** before and during therapy 4. **Avoid concurrent nephrotoxins** 5. **Monitor renal function** at baseline and every 2–3 days 6. **Limit duration** to 7–10 days when possible